What's Happening?
The Estée Lauder Companies have acquired a minority stake in the luxury skincare brand 111Skin, founded by Dr. Yannis Alexandrides. This strategic investment aims to bolster Estée Lauder's focus on science-backed beauty and treatment-led innovation. 111Skin, known
for its clinical skincare products, was initially developed to aid in post-procedure healing. The brand offers over 30 products, including its Black Diamond and Reparative collections, and is distributed through luxury retail, ecommerce, and spa channels. Estée Lauder's president and CEO, Stéphane de La Faverie, highlighted the shift in skincare towards products that deliver visible, treatment-inspired results. North America accounts for 40% of 111Skin's sales, with a strong presence in the UK, China, Europe, and Asia Pacific. Dr. Alexandrides will continue to lead the brand alongside its existing management team.
Why It's Important?
This investment by Estée Lauder signifies a growing trend in the beauty industry towards integrating scientific research and clinical insights into product development. By partnering with 111Skin, Estée Lauder is positioning itself to meet consumer demand for high-performance skincare solutions that offer tangible results. This move could enhance Estée Lauder's competitive edge in the luxury skincare market, potentially increasing its market share and influence. The collaboration may also drive innovation in skincare treatments, benefiting consumers seeking advanced solutions for skin health and rejuvenation.
